Physician profile
Fenglin Shi
NPI 1316111305
$1,055.37
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $88.83 · 2021: $216 · 2022: $19.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $213.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $82.94 | 2019-2020 | |
| Lundbeck LLC | $78.72 | 2019 | |
| Genzyme Corporation | $77.77 | 2019-2022 | |
| Biogen, INC. | $59.96 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $58.27 | 2019-2021 | |
| Ucb, INC. | $55.61 | 2019-2021 | |
| Kyowa Kirin, INC. | $53.60 | 2020-2021 | |
| Amgen INC. | $49.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.28 | 2021 | |
| Jazz Pharmaceuticals INC. | $38.16 | 2019 | |
| Supernus Pharmaceuticals, INC. | $37.17 | 2019 | |
| Travere Therapeutics, INC. | $29.47 | 2019 | |
| Allergan, INC. | $28.24 | 2019 | |
| Banner Life Sciences, LLC | $23.80 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $23.76 | 2019 | |
| Livanova USA, INC. | $22.63 | 2019 | |
| Upsher-Smith Laboratories LLC | $21.54 | 2020 | |
| Neurelis, INC. | $18.34 | 2021 | |
| Abbvie INC. | $17.14 | 2021 | |
| Genentech USA, INC. | $13.74 | 2019 | |
| Lilly USA, LLC | $12.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fenglin Shi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.